Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone

被引：0
|
作者：
Linda B Piller
Barry R Davis
Jeffrey A Cutler
William C Cushman
Jackson T Wright
Jeff D Williamson
Frans HH Leenen
Paula T Einhorn
Otelio S Randall
John S Golden
L Julian Haywood
机构：
[1] The University of Texas School of Public Health,Kaiser Permanente
[2] National Heart,Keck School of Medicine
[3] Lung,undefined
[4] and Blood Institute,undefined
[5] Memphis Veterans Affairs Medical Center,undefined
[6] Case Western Reserve University School of Medicine,undefined
[7] Wake Forest University,undefined
[8] University of Ottawa Heart Institute,undefined
[9] Howard University Medical School,undefined
[10] Mid-Atlantic States,undefined
[11] University of Southern California,undefined
[12] For a complete list of members of the ALLHAT Collaborative Research Group,undefined
来源：
Current Controlled Trials in Cardiovascular Medicine | 2002年 / 3卷
关键词：
heart failure; alpha-blocker; diuretic; clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to doxazosin and chlorthalidone
    Piller, LB
    Davis, BR
    Cutler, JA
    Cushman, WC
    Wright, JT
    Williamson, JD
    Leenen, FH
    Einhorn, PT
    Randall, OS
    Golden, JS
    Haywood, LJ
    [J]. CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2002, 3 (1):
  • [2] Review of heart failure events in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT): ALLHAT heart failure validation study
    Einhorn, P
    Davis, B
    Piller, L
    deLeon, B
    Simpson, L
    Kostis, J
    Levy, D
    Massie, B
    Nwachuku, C
    Black, H
    Cushman, W
    [J]. CIRCULATION, 2003, 108 (17) : 399 - 400
  • [3] Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone - The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Furberg, CD
    Wright, JT
    Davis, BR
    Cutler, JA
    Alderman, M
    Black, H
    Cushman, W
    Grimm, R
    Haywood, LJ
    Leenen, F
    Oparil, S
    Perry, HM
    Probstfield, J
    Whelton, P
    Payne, G
    Nwachuku, C
    Gordon, D
    Proschan, M
    Frommer, P
    Einhorn, P
    Hawkins, M
    Ford, C
    Pressel, S
    Piller, L
    Lusk, C
    Bettencourt, J
    Kimmel, B
    Geraci, T
    Walsh, S
    Rahman, M
    Juratovac, A
    Pospisil, R
    Brennan, K
    Carroll, L
    Sullivan, S
    Barone, G
    Christian, R
    Feldman, S
    Lucente, T
    Lewis, CE
    Jenkins, K
    McDowell, P
    Johnson, J
    Kingry, C
    Letterer, R
    Margolis, K
    Holland, L
    Jaeger-Fox, B
    Williamson, J
    Louis, G
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (15): : 1967 - 1975
  • [4] Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Grimm, RH
    Margolis, KL
    Papademetriou, V
    Cushman, WC
    Ford, CE
    Bettencourt, J
    Alderman, MH
    Basile, JN
    Black, HR
    DeQuattro, V
    Eckfeldt, J
    Hawkins, CM
    Perry, HM
    Proschan, M
    [J]. HYPERTENSION, 2001, 37 (01) : 19 - 27
  • [5] The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) Heart Failure Validation Study: Diagnosis and prognosis
    Einhorn, Paula T.
    Davis, Barry R.
    Massie, Barry M.
    Cushman, William C.
    Piller, Linda B.
    Simpson, Lara M.
    Levy, Daniel
    Nwachuku, Chuke E.
    Black, Henry R.
    [J]. AMERICAN HEART JOURNAL, 2007, 153 (01) : 42 - +
  • [6] Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Pressel, SL
    Davis, BR
    Wright, JT
    Geraci, TS
    Kingry, C
    Ford, CE
    Piller, LB
    Bettencourt, J
    Kimmel, B
    Lusk, C
    Parks, H
    Simpson, LM
    Nwachuku, C
    Furberg, CD
    [J]. CONTROLLED CLINICAL TRIALS, 2001, 22 (01): : 29 - 41
  • [7] Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Barzilay, JI
    Jones, CL
    Davis, BR
    Basile, JN
    Goff, DC
    Ciocon, JO
    Sweeney, ME
    Randall, OS
    [J]. DIABETES CARE, 2001, 24 (04) : 654 - 658
  • [8] Blood pressure control in Hispanic participants in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT).
    Margolis, KL
    Piller, LB
    Lewis, CE
    Goff, DC
    Cushman, WC
    Wright, JT
    Colon, PJ
    Ford, CE
    [J]. CIRCULATION, 2001, 103 (09) : 1348 - 1348
  • [9] Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)
    Davis, BR
    Cutler, JA
    Gordon, DJ
    Furberg, CD
    Wright, JT
    Cushman, WC
    Grimm, RH
    LaRosa, J
    Whelton, PK
    Perry, HM
    Alderman, MH
    Ford, CE
    Oparil, S
    Francis, C
    Proschan, M
    Pressel, S
    Black, HR
    Hawkins, CM
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) : 342 - 360
  • [10] Angioedema in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Piller, L
    Ford, C
    Davis, B
    Nwachuku, C
    Black, H
    Oparil, S
    Gappy, S
    Retta, T
    Probstfield, J
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 92A - 92A
12345